HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31

HCW Biologics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.23−0.01 (-0.81%)

Close on Oct 19, 2026

Market cap: $1.63M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

HCW Biologics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in HCW Biologics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in HCW Biologics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Aug 14, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HCWB.

Revenue growth700.2% · median -19.1%

Operating margin-115.3% · median -1018.9%

Net margin-83.8% · median -921.5%

Company	Revenue	Growth
EVMN	$10.00M	–
ACRS	$8.22M	-51.0%
HCWB	$6.66M	+700.2%
BOLT	$4.70M	+12.8%
TVRD	–	–
ZBIO	–	–

Company

Next earnings (est.): Nov 13, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Held by institutions: 5.6%
Auditor: Crowe LLP
SEC CIK: 1828673

Advertisement
300 × 250